Previous 10 | Next 10 |
DarioHealth (NASDAQ: DRIO) , a leader in the global digital health market, has published two studies in the leading peer-reviewed journal for digital health and medicine, the “Journal of Internet Medicine. ” The studies include a randomized controlled trial (“RCT”) de...
Dario Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health PR Newswire Studies include a Randomized Controlled Trial demonstrating significant reduction in perceived stress for teens NEW YORK , April 10, 2024 /PRNewswi...
DarioHealth (NASDAQ: DRIO) , a leader in the global digital therapeutics (“DTx”) market, has announced that it will release its financial results for the fourth quarter ended Dec. 31, 2023, before market opens on Thursday, March 28, 2024. At 8:30 a.m. Eastern Time on that same day, ...
Two National Employers Select Dario's Integrated Chronic Condition Solution to Improve Employee Health PR Newswire Dario selected to provide integrated approach to improve employee cardiometabolic health - including support for those taking a GLP-1 medication - musculoskeletal...
2024-03-28 14:54:02 ET DarioHealth Corp. (DRIO) Q4 2023 Earnings Conference Call March 28, 2024 08:30 ET Company Participants Kat Parrella - Investor Relations Erez Raphael - Chief Executive Officer Rick Anderson - President Ofer Leidner - Co-Founder, Twill ...
DarioHealth (NASDAQ: DRIO) , a leader in the global digital health market, is reporting on its fourth-quarter and full-year 2023 financial results; the company also releases a corporate and commercial update. Highlights of the report include $20.4 million full-year 2023 revenue, down from 2022 re...
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...
DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results PR Newswire Full-year 2023 revenue of $20.4 million reflects a decrease from 2022 revenue of $7.3 due to a managed decrease in B2C and strategic milestone revenue as the core B2...
DarioHealth (NASDAQ: DRIO) , a leader in the global digital therapeutics (“DTx”) market, has announced that it will release its financial results for the fourth quarter of fiscal 2023 for the three months ended Dec. 31, 2023, on Thursday, Mar. 28, 2024, before market open. Additiona...
DARIOHEALTH TO REPORT FOURTH QUARTER 2023 RESULTS ON THURSDAY, MARCH 28TH PR Newswire Company to host conference call and webcast at 8:30am ET NEW YORK , March 21, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital ...
News, Short Squeeze, Breakout and More Instantly...
DarioHealth (NASDAQ: DRIO) , a leader in the global digital health market, today announced a new contract with a national employer to provide its cardiometabolic solution with integrated support for GLP-1s to employees beginning in the third quarter of 2024. “The challenges associated with...
Dario Expands GLP-1 Solution Client Base with New Employer Contract PR Newswire Dario's leading behavior change solutions continue to win interest in the employer, payer and pharmaceutical markets NEW YORK , July 16, 2024 /PRNewswire/ -- DarioHealth Corp....
DarioHealth (NASDAQ: DRIO) , a leader in the global digital health market, today announced two new studies presented this past weekend at the 84th Annual American Diabetes Association (“ADA”) Scientific Sessions in Orlando. According to the announcement, the first study provides an ...